NuVasive (NUVA) & Globus Medical (GMED) M&A Case

#NuVasive's BoD unanimously approved the M&A deal with  #GlobusMedical.
$NUVA #shareholders will receive 0.75 of $GMED A stock.
#Investors suspect that the pricing terms of the $NUVA & GMED #M&A deal are unfair.
On February 9, 2023, NuVasive (NASDAQ: NUVA), the leader in spine technology innovation, and Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, announced they have entered into a definitive agreement to combine in an all-stock transaction.

Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, NuVasive (NUVA) shareholders will receive 0.75 of a share of Globus Medical Class A common stock for each share of NuVasive common stock owned at the closing of the transaction. 

Based on this exchange ratio, the implied share price for NuVasive (NUVA) would be $57.72, an equity value of $3.1 billion, based on Globus Medical's closing share price on February 8. Following the close of the transaction, NuVasive shareholders will own approximately 28% of the combined company, and Globus Medical shareholders will own approximately 72%, on a fully diluted basis.

Investors may have reasons to suspect that the pricing terms of the M&A transaction are unfair and that the Company BoD breached fiduciary duties to shareholders.

Case Status

Attorney Investigation

Alleged Offence

Mismanagement,

Financial Misrepresentation,

Failure to Disclose,

Malpractice,

Negligence,

Breach of Fiduciary duty,

Omissions

Suspected Party

Directors,

Management,

Shareholder,

Investment Bank,

Service Provider

Security Type

Stocks

Trade Direction

Long

Shock Event Date

03/09/2023

NuVasive (NUVA) & Globus Medical (GMED) M&A Case

Collecting participants…